Benjamin Hickey Mirati Therapeutics, Inc. (MRTX) insider trading activity

Benjamin Hickey is EVP, Chief Commercial Officer of Mirati Therapeutics, Inc.. Currently has a direct ownership of 0 shares of MRTX, which is worth approximately $0. The most recent transaction as insider was on Jan 23, 2024, when has been sold 117,028 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

Benjamin Hickey Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 23 2024	SELL Sale (or disposition) back to the issuer	-	117,028 Reduced 100.0%	0 Common Stock
Jan 16 2024	SELL Open market or private sale	$94,254 $59.02 p/Share	1,597 Reduced 1.35%	117,028 Common Stock
Jan 08 2024	SELL Open market or private sale	$123,142 $58.92 p/Share	2,090 Reduced 1.73%	118,625 Common Stock
Dec 29 2023	BUY Grant, award, or other acquisition	$999,983 $58.75 p/Share	17,021 Added 12.36%	120,715 Common Stock
Dec 13 2023	SELL Open market or private sale	$125,807 $56.67 p/Share	2,220 Reduced 2.1%	103,694 Common Stock
Aug 09 2023	BUY Grant, award, or other acquisition	$824,989 $37.0 p/Share	22,297 Added 17.39%	105,914 Common Stock
Jan 20 2023	BUY Grant, award, or other acquisition	-	36,394 Added 30.33%	83,617 Common Stock
Jan 17 2023	SELL Open market or private sale	$66,367 $42.38 p/Share	1,566 Reduced 3.21%	47,223 Common Stock
Jan 09 2023	SELL Open market or private sale	$94,732 $45.37 p/Share	2,088 Reduced 4.1%	48,789 Common Stock
Dec 21 2022	SELL Open market or private sale	$131,251 $40.41 p/Share	3,248 Reduced 6.0%	50,877 Common Stock
Dec 19 2022	BUY Grant, award, or other acquisition	-	19,149 Added 26.13%	54,125 Common Stock
Jan 18 2022	SELL Open market or private sale	$75,541 $120.48 p/Share	627 Reduced 1.76%	34,976 Common Stock
Jan 14 2022	BUY Grant, award, or other acquisition	-	10,755 Added 23.2%	35,603 Common Stock
Jan 07 2022	SELL Open market or private sale	$266,986 $135.94 p/Share	1,964 Reduced 7.33%	24,848 Common Stock
Mar 19 2021	SELL Open market or private sale	$418,271 $176.56 p/Share	2,369 Reduced 8.12%	26,812 Common Stock
Mar 19 2021	BUY Exercise of conversion of derivative security	$270,848 $114.33 p/Share	2,369 Added 7.51%	29,181 Common Stock
Jan 15 2021	BUY Grant, award, or other acquisition	-	7,023 Added 20.76%	26,812 Common Stock
Jan 07 2021	SELL Open market or private sale	$448,474 $215.82 p/Share	2,078 Reduced 9.5%	19,789 Common Stock

Also insider at

SURF

Surface Oncology, Inc. Healthcare

Director

MURA

Mural Oncology plc

BMY

BRISTOL MYERS SQUIBB CO Healthcare

President, RayzeBio Org.

Benjamin Hickey

EVP, Chief Commercial Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRTX shares.

Notify only if

Value

Insider Trading

Get notified when an Mirati Therapeutics, Inc. insider buys or sells MRTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Mirati Therapeutics, Inc.

Track Activities on MRTX

Account